Predictors and Prognostic Factors of Myasthenia Gravis Outcome

RECRUITING

NCT05214612

Sponsor: Assiut University

Summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Key Details

Gender

All

Age Range

16 Years - Any

Study Type

OBSERVATIONAL

Enrollment

30

Start Date

2022-01-01

Completion Date

2025-03-31

Last Updated

2024-07-31

Healthy Volunteers

No

Conditions

Myasthenia Gravis Autoimmune Diseases of the Nervous System Neuromuscular Junction Diseases Thymoma Thymus Hyperplasia Nervous System Diseases Myasthenia Gravis, Generalized Myasthenia Gravis, Ocular Myasthenia Gravis Crisis Myasthenia Gravis With Exacerbation (Disorder)Myasthenia Gravis, Adult Form Myasthenia Gravis, Juvenile Form

Interventions

COMBINATION_PRODUCT

Drug treatment of myasthenia gravis and treatment of crisis

Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis

Locations (1)

Assiut University

Asyut, Egypt

Clinical Research Directory